新規免疫チェックポイント阻害薬ヒト型抗ヒトPD-1抗体ニボルマブ(オプジーボ®点滴静注20 mg,100 mg)の薬理学的特性および臨床効果

About this Attention Score

• In the top 25% of all research outputs scored by Altmetric
• One of the highest-scoring outputs from this source (#3 of 796)
• High Attention Score compared to outputs of the same age (92nd percentile)
• High Attention Score compared to outputs of the same age and source (99th percentile)